SEC Tracker
Get the app

Tivic Health Systems VBIO

Tivic Health Systems Q2 FY25: revenue $86K, down 39%; diluted EPS −$2.19

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Tivic Health Systems reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$86K−39% from $140K in Q2 FY2410-Q income statement, on EDGAR
  2. Net income−$1.9MAgainst −$1.3M in Q2 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$2.19Against −$5.44 in Q2 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.2M−68% from $3.7M in Q2 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations−$1.8MAgainst −$1.3M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Tivic Health Systems files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Healthy Extracts HYEX public float $4M, Jun 30, 2025
  2. Theriva Biologics TOVX public float $4M, Jun 30, 2025
  3. Jaguar Health JAGX public float $4M, Jun 30, 2025
  4. China Pharma Holdings CPHI public float $4M, Jun 30, 2025
  5. Synlogic SYBX public float $4M, Jun 30, 2025